歌礼制药有限公司(股票代码：01672)于2026年7月17日公告，该公司在香港联交所场内回购30万股普通股，占公司已发行股本(不包括库藏股)约0.0283%。每股回购价格介乎每股8.19港元至9.63港元之间，合计耗资约258.03万港元。
公告显示，回购完成后，公司已发行普通股数量维持在1,061,370,845股，另有7,084,210股为库藏股，总股本为1,068,455,055股。此外，购回授权的决议已于2026年6月29日通过，可回购股份总数为106,137,084股。截至公告日，公司已累计在交易所和其他证券交易所回购1,045,000股，占购回授权获批时已发行股本(不包括库藏股)的约0.0985%。
公司并表示，此次回购严格遵守香港联交所证券上市规则及相关法律法规，公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.